Clinical Trials
3 trialsNCT03913949 2026-05-01
A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies
Ascentage Pharma Group Inc.
Phase 1 Active not recruiting
NCT05147467 2026-03-27
Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 2 Recruiting
NCT04494503 2025-04-16
Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
Ascentage Pharma Group Inc.
Phase 1/2 Recruiting